Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Chris Packard Articles

Preventing cardiovascular disease: the value of early signs of cardiac injury

Preventing cardiovascular disease: the value of early signs of cardiac injury

Professor Packard (University of Glasgow, UK) discusses how early signs of cardiac dysfunction/injury (such as troponin I, a biomarker of cardiomyocyte damage or stress) may help in identifying individuals at risk of cardiovascular events, with insights from the WOSCOPS study.  Translating these insights to primary…

read more »
Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?

Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?

Professor Packard, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK discusses follow-up data from major statin trials and considers the potential mechanism for the legacy effect seen in some trials, such as WOSCOPS. These findings raise a key question: Would phased…

read more »
PCSK9 inhibitors, legacy effects and long-term benefits

PCSK9 inhibitors, legacy effects and long-term benefits

Prof Chris J Packard, College of Medical, Veterinary and Life Sciences, University of Glasgow, discusses the potential of profound LDL lowering to alter the natural history of atherosclerotic disease Genetic, epidemiological, clinical trial and pathological data come together to focus intervention strategies on LDL as…

read more »